What a day for Joseph Edelman’s Perceptive Advisors.Pfizer’s announcement that it agreed to acquire Array Biopharma for $10.64 billion in cash not only sent the shares of the cancer drug developer soaring, it sharply lifted the stocks of many other biopharmaceutical companies, especially those trying